Status:
COMPLETED
Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease
Lead Sponsor:
Nycomed
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
12+ years
Brief Summary
The aim of this study was to evaluate the effect of 14 days treatment with Pantoprazole 40 mg and 20 mg on gastroesophageal reflux disease (GERD) related symptoms in a large patient population.
Eligibility Criteria
Inclusion
- Main inclusion criteria:
- Outpatients with gastroesophageal reflux disease (GERD)
- Main exclusion criteria:
- Criteria as defined in the Summary of Product Characteristics
Exclusion
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
4188 Patients enrolled
Trial Details
Trial ID
NCT00829738
Start Date
January 1 2009
End Date
June 1 2009
Last Update
May 8 2012
Active Locations (717)
Enter a location and click search to find clinical trials sorted by distance.
1
Nycomed Deutschland GmbH
Aachen, Germany, 52072
2
Nycomed Deutschland GmbH
Aachen, Germany, 52078
3
Nycomed Deutschland GmbH
Ahrensburg, Germany, 22926
4
Nycomed Deutschland GmbH
Alpenrod, Germany, 57642